Fujian Haixi Pharmaceuticals Schedules Key Board Meeting to Approve 2025 Annual Results

Major Developments Ahead for Shareholders

Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) has announced that its Board of Directors will convene a crucial meeting on Monday, 30 March 2026. This meeting will focus on multiple significant matters that are highly relevant to investors and could potentially influence the company’s share price.

Key Points for Investors

• Approval of Annual Results: The primary agenda is to consider and approve the Group’s annual results for the year ended 31 December 2025. The release of annual financial results is a key event that often impacts market sentiment and share prices, as it provides insights into the company’s performance and financial health over the past year.
• Final Dividend Recommendation: The Board will also discuss and may recommend the payment of a final dividend. Any announcement regarding dividends is closely watched by shareholders, as it directly affects shareholder returns and signals management’s confidence in the company’s cash flows.
• Other Business Matters: The Board may transact additional business during the meeting. While specifics were not disclosed, any material decisions or strategic initiatives could be price sensitive.

Board Composition

The announcement also reiterates the current composition of the Board:

• Executive Directors: Dr. Kang Xinshan (Chairman), Ms. Feng Yan, Dr. Chen Guangming, Dr. Chen Shuyi
• Non-executive Directors: Mr. Xu Dong, Mr. Wang Xinkun
• Independent Non-executive Directors: Mr. Gong Weimin, Ms. Wang Shan Shan, Ms. Pu Meiting

What Shareholders Should Watch For

• Potential Price Sensitivity: The outcome of the meeting—particularly the release of annual results and any dividend declaration—could have a direct impact on Fujian Haixi Pharmaceuticals’ share price. Investors are advised to monitor the company’s announcements closely around this date.
• Market Expectations: The market will be seeking details on the company’s operational performance, profitability, and outlook for the coming year. Any results that significantly exceed or fall short of expectations could trigger substantial share price movement.

The company has made this announcement in compliance with regulations set by the Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited, which take no responsibility for the contents of the announcement.

Conclusion

The upcoming Board meeting on 30 March 2026 is a key event for all stakeholders. The decisions made regarding the annual results and dividend payments will be watched closely by investors, and any new business or strategic developments disclosed could further impact the share price. Shareholders are encouraged to remain vigilant for further updates from the company.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making investment decisions.

View HAIXI PHARMA Historical chart here